ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

MHC-Class-II Specific Sensitization in a Non-Human Primate Model of Sensitzation

C. Burghuber,1,2 J. Kwun,1 A. Gibby,1 N. Iwakoshi,1 S. Knechtle.1

1Emory University, Atlanta, GA
2Medical University Vienna, Vienna, Austria.

Meeting: 2015 American Transplant Congress

Abstract number: C9

Keywords: Alloantibodies, Inflammation, Sensitization

Session Information

Date: Monday, May 4, 2015

Session Name: Poster Session C: Antigen Presenting Cells in Alloimmune Responses/B Cells and Antibody in Alloimmune Responses

Session Time: 5:30pm-6:30pm

 Presentation Time: 5:30pm-6:30pm

Location: Exhibit Hall E

Related Abstracts
  • Distinct Subtypes of Rejection in a Novel Non Human Primate Model of Sensitization
  • Regulatory Tolerance Across a Full MHC Barrier Is More Robust Than Tolerance Across a Class I MHC Disparity Alone

[Background] Sensitization before transplantation and de novo alloantibodies affect a significant number of patients awaiting kidney transplantation. The type of anti-HLA antibody varies with subgroups that express MHC class I alone, MHC class II alone or both. The mechanisms that direct MHC Class I or II sensitization are not well understood. Using a non-human primate model of sensitization, we have performed a series of experiments to investigate the mechanisms involved in donor specific sensitization. With this data we report that a unique combination of donor antigen combined with adjuvant therapy results in MHC class II specific sensitization.

[Methods] Thirteen fully mismatched rhesus macaques were sensitized via skin exchange (SKIN-group). Four comparable animals twice received equal amounts of donor peripheral blood mononuclear cells (PBMC-group) intravenously and intradermally, the latter after adsorption with aluminum hydroxide gel suspension as adjuvant. Immunologic responses were monitored by T- and B-cell flow crossmatches (FXM). FXM were considered positive when reaching MFI-ratio > 2 (two-fold MFI value compared to baseline). We correlated FXM results with the human FlowPRA bead assay in 1 animal of each group.

[Results] All SKIN-animals showed a positive T- and B-cell FXM at peak (mean MFI-ratios 9.2+/-7.1 and 6.5+/-3.2 respectively). PBMC-animals showed negative T-cell FXM at all time points (mean peak 1.49+/-0.3), but all had a strongly positive B-cell FXM (mean peak 9.19+/-4.9). The FlowPRA assay was positive for MHC class I and II in the SKIN-animal but isolated positive for class II in the PBMC-animal.

[Conclusion] These results suggest that MHC class II specific sensitization may be controlled by inflammatory signals during donor antigens sensitization. Although the mechanism of this phenomenon is unclear, these results support further investigation into the role of innate immunologic mechanisms during sensitization.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Burghuber C, Kwun J, Gibby A, Iwakoshi N, Knechtle S. MHC-Class-II Specific Sensitization in a Non-Human Primate Model of Sensitzation [abstract]. Am J Transplant. 2015; 15 (suppl 3). https://atcmeetingabstracts.com/abstract/mhc-class-ii-specific-sensitization-in-a-non-human-primate-model-of-sensitzation/. Accessed April 15, 2021.

« Back to 2015 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Home
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.